Johnson & Johnson Reports Third-Quarter 2013 Results - - BioPharm International

ADVERTISEMENT

Johnson & Johnson Reports Third-Quarter 2013 Results


Johnson & Johnson reported its 2013 third-quarter results, with sales of $17.6 billion up 3.1% as compared to the third quarter of 2012, the company announced in a press release. Operational results increased 4.7% and the negative impact of currency was 1.6%. International sales, up 4.2%, reflected operational growth of 7.1% and a negative currency impact of 2.9% and outpaced domestic US sales, which increased 1.7%.

For the third quarter of 2013, net earnings (attributable to Johnson & Johnson) were $3.0 billion and diluted earnings per share were $1.04. The company increased its earnings guidance for full-year 2013 to $5.44–5.49 per share, which excludes the impact of special items.

Worldwide pharmaceutical sales of $7.0 billion for the third quarter represented an increase of 9.9% over the previous year, with operational growth of 10.9% and a negative impact from currency of 1.0%. Domestic sales increased 7.9%. International sales increased 12.0%, which reflected an operational increase of 14.0% and a negative currency impact of 2.0%.

Primary contributors to operational sales growth were Invega Sustenna/Xeplion (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; Remicade (infliximab) and Simponi (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; Stelara (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; Velcade (bortezomib), a treatment for multiple myeloma; Prezista (darunavir), a treatment for HIV; and sales of new products.

Source: Johnson & Johnson

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines

Click here